The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.
News & Analysis: Immunomedics
Gilead's stock has been volatile, but if you had bought it early, right after its IPO in 1992, you would have done quite well.
Results from a study of Trodelvy presented over the weekend suggest Gilead Sciences' $21 billion buyout offer was a smart move.
Find out what's behind their big run-ups to see if they can make it happen again.
Want to invest in coronavirus vaccine stocks but are worried about their risks? This portfolio will have you covered.
It's going to be a while before we know if Gilead's $21 billion deal will pay off.
Immunomedics ties the knot with Gilead Sciences in a $21 billion merger agreement.
The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.
Sales of these recently launched products could make a big difference for the companies behind them.
This biotech's advanced breast cancer drug got the green light from the FDA.